Brief: Visen Pharmaceuticals Says NMPA Approves Lonapegsomatropin (Skytrofa) For Injection
26/01/2026 16:58
Jan 26 (Reuters) - Visen Pharmaceuticals 2561.HK: NMPA APPROVES LONAPEGSOMATROPIN (SKYTROFA) FOR INJECTION Further company coverage: 2561.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Visen Pharmaceuticals
See all newsBrief: Visen Pharmaceuticals Posts Loss For Year Of RMB253.4 Million
Brief: Visen Pharmaceuticals Says NMPA Approves Lonapegsomatropin (Skytrofa) For Injection
Brief: Visen Pharmaceuticals Appoints Lu Ying As CFO
Brief: Visen Pharmaceuticals Logs HY Loss RMB118 Mln
Brief: Visen Pharmaceuticals Says Number Of Offer Shares Under Global Offering 11.4 Million